Nasdaq:ONMD
OneMedNet Corp
A niche player in healthcare networking infrastructure facing significant profitability headwinds amid shrinking revenues.
Key Metrics
Investment Thesis
Bull Case
An investor might consider ONMD if they believe in a potential acquisition scenario given its specialized niche assets and existing client base. The current stock price likely reflects extreme pessimism, offering a high-risk lottery ticket option for deep value seekers betting on a complete operational reset. Any successful pivot to higher-margin products could instantly improve unit economics due to the low asset base.
Bear Case
The company faces existential risks with negative shareholders' equity and an inability to generate positive cash flow from operations. Continued revenue decline and mounting losses erode any remaining book value, making a public listing increasingly untenable. The reliance on financing proceeds rather than organic growth signals that the core business model is broken.
About OneMedNet Corp
OneMedNet Corp (ONMD) operates within the healthcare technology sector, providing specialized medical network solutions and data services. The company serves markets requiring advanced connectivity and operational efficiency for medical entities. Key revenue streams derive from service contracts and potentially licensing of proprietary medical network protocols.
Analysis
Management Discussion
The company reported a net loss of $10.1 million in 2024, continuing a deteriorating trend from a $23.2 million loss the prior year. Revenue dropped from $1.0 million to $643,000, while operating expenses remained elevated at over $9.0 million. Despite cash flow from operations being negative, the firm utilized financing activities to maintain liquidity, but the burn rate is unsustainable without a turnaround.
Industry Overview
The healthcare technology industry is rapidly evolving towards interoperability and digital health records, requiring robust network infrastructure. Companies in this sector face intense competition from large tech firms and established medical device manufacturers who offer integrated solutions. Regulatory changes regarding data privacy are increasing barriers to entry but also protecting incumbents with compliant networks.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $1.0M | $643.0K |
| Cost of Revenue | $0 | $1.1M | $924.0K |
| Gross Profit | $0 | $-127.9K | $-281.0K |
| Operating Expenses | $5.3M | $8.2M | $9.3M |
| Operating Income | $-5.3M | $-8.4M | $-9.6M |
| R&D | — | $1.6M | $1.5M |
| G&A | — | $5.3M | $7.0M |
| Marketing | — | $1.1M | $830.0K |
| Stock-Based Comp | $2.8M | — | $628.0K |
| D&A | — | $28.0K | $57.0K |
| Other OpEx | — | $226.3K | $0 |
| Non-Operating Income | $5.9M | $0 | $-522.0K |
| Interest Expense | — | $749.2K | — |
| Pre-Tax Income | $551.5K | $-8.4M | $-10.1M |
| Income Tax | $214.8K | $14.8M | $2.0K |
| Continuing Ops | $336.7K | $-23.2M | $-10.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $336.7K | $-23.2M | $-10.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $336.7K | $-23.2M | $-10.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $30.9K | $364.2K | $3.6M |
| Cash & Equivalents | $30.9K | $47.0K | $172.0K |
| Accounts Receivable | — | $151.6K | $213.0K |
| Prepaid Expenses | — | $165.5K | $385.0K |
| Other Current Assets | $0 | $0 | $2.8M |
| Long-Term Assets | $29.0M | $98.9K | $108.0K |
| PP&E (Net) | — | $98.9K | $108.0K |
| Other LT Assets | — | $0 | $0 |
| Total Assets | $29.1M | $463.1K | $3.7M |
| Current Liabilities | $2.0M | $12.8M | $19.2M |
| Taxes Payable | $214.8K | $120.0K | — |
| Other Current Liab | $1.8M | $12.7M | — |
| Long-Term Liabilities | $7.1M | $489.6K | $449.0K |
| Total Liabilities | $9.1M | $13.3M | $19.7M |
| Shareholders' Equity | $19.9M | $-12.9M | $-15.9M |
| Paid-In Capital | $2.8M | $42.2M | $86.1M |
| Retained Earnings | $-11.6M | $-55.1M | $-101.6M |
| Total L&E | $29.1M | $463.1K | $3.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $336.7K | $-23.2M | $-10.1M |
| Non-Cash Adjustments | $-3.0M | $29.9M | $1.1M |
| Working Capital Changes | $1.7M | $1.5M | $2.1M |
| Cash from Operations | $-940.5K | $8.2M | $-7.0M |
| Capital Expenditures | — | $43.8K | $51.0K |
| Cash from Investing | $-2.2M | $-43.8K | $-2.0M |
| Debt Repayments | — | — | $200.0K |
| Cash from Financing | $2.8M | $-8.4M | $9.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-422.3K | $-254.7K | $125.0K |
| Beginning Cash | $453.2K | $301.7K | $47.0K |
| Ending Cash | $30.9K | $47.0K | $172.0K |
Frequently Asked Questions
How does OneMedNet Corp make money?
The company's financials suggest a primary segment focused on direct medical service or data provision, with secondary segments potentially involving technology licensing or managed services. Revenue contraction indicates a possible reliance on legacy contracts or a struggling new product line that has not yet achieved scale.
What are the main risks for ONMD?
Severe financial distress is evident with negative net income, a significant retained earnings deficit, and current liabilities far exceeding current assets. Revenue decline over the past two years indicates a loss of market share or product obsolescence. High operating expenses relative to minimal revenue suggest inefficient cost structures or failing growth strategies.
What is ONMD's competitive advantage?
Potential advantages include proprietary access to specific medical network data streams and established relationships with specialized healthcare clients. The company may possess deep domain expertise in niche regulatory compliance for health data transmission. Low capital expenditures relative to assets suggest an asset-light operational model if successful.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.